Changes in IgG subclasses of donor specific anti-HLA antibodies following bortezomib-based therapy for antibody mediated rejection. Academic Article uri icon


MeSH Major

  • Boronic Acids
  • Graft Rejection
  • HLA Antigens
  • Immunoglobulin G
  • Organ Transplantation
  • Pyrazines


  • The predominant anti-HLA IgG subclass during antibody mediated rejection episodes is IgG1. Class I DSA IgG subclasses respond to single cycle of bortezomib-based therapy more frequently as compared to Class II DSA IgG subclasses. High titer Class II DSA IgG subclasses are less likely to respond to single cycle bortezomib-based therapy. Future studies are needed to determine if the response to bortezomib-based therapy is dependent on the type of DSA and/or the strength of the DSA at the time of antibody mediated rejection episode.

publication date

  • December 2012



  • Academic Article



  • eng

PubMed ID

  • 23721027

Additional Document Info

start page

  • 229

end page

  • 35